1. |
赵俊松, 崔利, 何江波, 等. 上海22351例无症状体检者低剂量CT肺癌筛查及随访结果初步分析. 诊断学理论与实践, 2019, 18(2): 183-188.
|
2. |
Church TR, Black WC, Aberle DR, et al. Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med, 2013, 368(21): 1980-1991.
|
3. |
李为希, 周洁, 张芬, 等. 低剂量螺旋CT对高危人群的肺癌筛查结果分析. 中国肿瘤, 2019, 28(12): 896-900.
|
4. |
Lopes Pegna A, Picozzi G, Falaschi F, et al. Four-year results of low-dose CT screening and nodule management in the ITALUNG trial. J Thorac Oncol, 2013, 8(7): 866-875.
|
5. |
He YT, Zhang YC, Shi GF, et al. Risk factors for pulmonary nodules in north China: A prospective cohort study. Lung Cancer, 2018, 120: 122-129.
|
6. |
Sihoe ADL, Petersen RH, Cardillo G. Multiple pulmonary ground glass opacities: is it time for new guidelines? J Thorac Dis, 2018, 10(11): 5970-5973.
|
7. |
Trinidad López C, Delgado Sánchez-Gracián C, Utrera Pérez E, et al. Incidental pulmonary nodules: characterization and management. Radiologia, 2019, 61(5): 357-369.
|
8. |
中华医学会呼吸病学分会肺癌学组, 中国肺癌防治联盟专家组. 肺结节诊治中国专家共识(2018年版). 中华结核和呼吸杂志, 2018, 41(10): 763-771.
|
9. |
MacMahon H, Naidich DP, Goo JM, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: From the Fleischner Society 2017. Radiology, 2017, 284(1): 228-243.
|
10. |
van Riel SJ, Ciompi F, Jacobs C, et al. Malignancy risk estimation of screen-detected nodules at baseline CT: comparison of the PanCan model, Lung-RADS and NCCN guidelines. Eur Radiol, 2017, 27(10): 4019-4029.
|
11. |
Ren Y, Huang S, Dai C, et al. Germline predisposition and copy number alteration in pre-stage lung adenocarcinomas presenting as ground-glass nodules. Front Oncol, 2019, 9: 288.
|
12. |
Li X, Hu B, Li H, et al. Application of artificial intelligence in the diagnosis of multiple primary lung cancer. Thorac Cancer, 2019, 10(11): 2168-2174.
|
13. |
中国肺癌防治联盟, 中华医学会呼吸病学分会肺癌学组, 中国医师协会呼吸医师分会肺癌工作委员会. 肺癌筛查与管理中国专家共识. 国际呼吸杂志, 2019, 39(21): 1604-1615.
|
14. |
Garcia-Velloso MJ, Bastarrika G, de-Torres JP, et al. Assessment of indeterminate pulmonary nodules detected in lung cancer screening: Diagnostic accuracy of FDG PET/CT. Lung Cancer, 2016, 97: 81-86.
|
15. |
Chun EJ, Lee HJ, Kang WJ, et al. Differentiation between malignancy and inflammation in pulmonary ground-glass nodules: The feasibility of integrated (18)F-FDG PET/CT. Lung Cancer, 2009, 65(2): 180-186.
|
16. |
Taralli S, Scolozzi V, Foti M, et al. (18)F-FDG PET/CT diagnostic performance in solitary and multiple pulmonary nodules detected in patients with previous cancer history: reports of 182 nodules. Eur J Nucl Med Mol Imaging, 2019, 46(2): 429-436.
|
17. |
Messerli M, Kluckert T, Knitel M, et al. Ultralow dose CT for pulmonary nodule detection with chest x-ray equivalent dose — a prospective intra-individual comparative study. Eur Radiol, 2017, 27(8): 3290-3299.
|
18. |
Dewes P, Frellesen C, Al-Butmeh F, et al. Comparative evaluation of non-contrast CAIPIRINHA-VIBE 3T-MRI and multidetector CT for detection of pulmonary nodules: In vivo evaluation of diagnostic accuracy and image quality. Eur J Radiol, 2016, 85(1): 193-198.
|
19. |
Huber A, Landau J, Ebner L, et al. Performance of ultralow-dose CT with iterative reconstruction in lung cancer screening: limiting radiation exposure to the equivalent of conventional chest X-ray imaging. Eur Radiol, 2016, 26(10): 3643-3652.
|
20. |
Ludwig M, Chipon E, Cohen J, et al. Detection of pulmonary nodules: a clinical study protocol to compare ultra-low dose chest CT and standard low-dose CT using ASIR-V. BMJ Open, 2019, 9(8): e025661.
|
21. |
Larici AR, Farchione A, Franchi P, et al. Lung nodules: size still matters. Eur Respir Rev, 2017, 26(146): 170025.
|
22. |
周清华, 范亚光, 王颖, 等. 中国肺癌低剂量螺旋CT筛查指南(2018年版). 中国肺癌杂志, 2018, 21(2): 67-75.
|
23. |
Ettinger DS, Wood DE, Aisner DL, et al. Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2017, 15(4): 504-535.
|
24. |
Horeweg N, van Rosmalen J, Heuvelmans MA, et al. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. Lancet Oncol, 2014, 15(12): 1332-1341.
|
25. |
Missrie I, Hochhegger B, Zanon M, et al. Small low-risk pulmonary nodules on chest digital radiography: can we predict whether the nodule is benign? Clin Radiol, 2018, 73(10): 902-906.
|
26. |
Heuvelmans MA, Walter JE, Vliegenthart R, et al. Disagreement of diameter and volume measurements for pulmonary nodule size estimation in CT lung cancer screening. Thorax, 2018, 73(8): 779-781.
|
27. |
Koslow M, Young JR, Yi ES, et al. Rheumatoid pulmonary nodules: clinical and imaging features compared with malignancy. Eur Radiol, 2019, 29(4): 1684-1692.
|
28. |
Liu Y, Wang H, Li Q, et al. Radiologic features of small pulmonary nodules and lung cancer risk in the national lung screening trial: A nested case-control study. Radiology, 2018, 286(1): 298-306.
|
29. |
Webb WR, Higgins CB. Thoracic imaging: pulmonary and cardiovascular radiology. Third edition. Philadelphia: Wolters Kluwer, 2016. 952-1065.
|
30. |
Walter JE, Heuvelmans MA, Ten Haaf K, et al. Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening study. Thorax, 2019, 74(3): 247-253.
|
31. |
Silva M, Sverzellati N, Manna C, et al. Long-term surveillance of ground-glass nodules: evidence from the MILD trial. J Thorac Oncol, 2012, 7(10): 1541-1546.
|
32. |
Wu F, Tian SP, Jin X, et al. CT and histopathologic characteristics of lung adenocarcinoma with pure ground-glass nodules 10 mm or less in diameter. Eur Radiol, 2017, 27(10): 4037-4043.
|
33. |
Revel MP, Mannes I, Benzakoun J, et al. Subsolid lung nodule classification: A CT criterion for improving interobserver agreement. Radiology, 2018, 286(1): 316-325.
|
34. |
Heuvelmans MA, Walter JE, Peters RB, et al. Relationship between nodule count and lung cancer probability in baseline CT lung cancer screening: The NELSON study. Lung Cancer, 2017, 113: 45-50.
|
35. |
Walter JE, Heuvelmans MA, de Bock GH, et al. Relationship between the number of new nodules and lung cancer probability in incidence screening rounds of CT lung cancer screening: The NELSON study. Lung Cancer, 2018, 125: 103-108.
|
36. |
Slatore CG, Wiener RS. Pulmonary nodules: A small problem for many, severe distress for some, and how to communicate about it. Chest, 2018, 153(4): 1004-1015.
|
37. |
Walter JE, Heuvelmans MA, Bock GH, et al. Characteristics of new solid nodules detected in incidence screening rounds of low-dose CT lung cancer screening: the NELSON study. Thorax, 2018, 73(8): 741-747.
|
38. |
Karki A, Shah R, Fein A. Multiple pulmonary nodules in malignancy. Curr Opin Pulm Med, 2017, 23(4): 285-289.
|
39. |
Sato Y, Fujimoto D, Morimoto T, et al. Natural history and clinical characteristics of multiple pulmonary nodules with ground glass opacity. Respirology, 2017, 22(8): 1615-1621.
|
40. |
Hattori A, Matsunaga T, Takamochi K, et al. Surgical management of multifocal ground-glass opacities of the lung: Correlation of clinicopathologic and radiologic findings. Thorac Cardiovasc Surg, 2017, 65(2): 142-149.
|
41. |
Marcus MW, Duffy SW, Devaraj A, et al. Probability of cancer in lung nodules using sequential volumetric screening up to 12 months: the UKLS trial. Thorax, 2019, 74(8): 761-767.
|
42. |
Winter A, Aberle DR, Hsu W. External validation and recalibration of the Brock model to predict probability of cancer in pulmonary nodules using NLST data. Thorax, 2019, 74(6): 551-563.
|
43. |
Tanner NT, Porter A, Gould MK, et al. Physician assessment of pretest probability of malignancy and adherence with guidelines for pulmonary nodule evaluation. Chest, 2017, 152(2): 263-270.
|
44. |
Silvestri GA, Tanner NT, Kearney P, et al. Assessment of plasma proteomics biomarker's ability to distinguish benign from malignant lung nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial. Chest, 2018, 154(3): 491-500.
|
45. |
Ather S, Kadir T, Gleeson F. Artificial intelligence and radiomics in pulmonary nodule management: current status and future applications. Clin Radiol, 2020, 75(1): 13-19.
|